Cargando…

1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis

BACKGROUND: Febrile neutropenia (FN) is a common complication of cancer therapy and often necessitates prolonged antibiotic treatment. Antibiotic de-escalation can be challenging given tenuous clinical status. Furthermore, a microbiological or clinical etiology is identified in a minority of FN pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinh, Trang D, Strnad, Luke, Damon, Lloyd E, Dzundza, John H, Graff, Larissa R, Griffith, Laura M, Hilts-Horeczko, Alexandra, Olin, Rebecca L, Shenoy, Samantha, DeVoe, Catherine, Wang, Lusha, Rodriguez-Monguio, Rosa, Doernberg, Sarah B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810922/
http://dx.doi.org/10.1093/ofid/ofz360.953
_version_ 1783462353384243200
author Trinh, Trang D
Strnad, Luke
Damon, Lloyd E
Dzundza, John H
Graff, Larissa R
Griffith, Laura M
Hilts-Horeczko, Alexandra
Olin, Rebecca L
Shenoy, Samantha
DeVoe, Catherine
Wang, Lusha
Rodriguez-Monguio, Rosa
Doernberg, Sarah B
author_facet Trinh, Trang D
Strnad, Luke
Damon, Lloyd E
Dzundza, John H
Graff, Larissa R
Griffith, Laura M
Hilts-Horeczko, Alexandra
Olin, Rebecca L
Shenoy, Samantha
DeVoe, Catherine
Wang, Lusha
Rodriguez-Monguio, Rosa
Doernberg, Sarah B
author_sort Trinh, Trang D
collection PubMed
description BACKGROUND: Febrile neutropenia (FN) is a common complication of cancer therapy and often necessitates prolonged antibiotic treatment. Antibiotic de-escalation can be challenging given tenuous clinical status. Furthermore, a microbiological or clinical etiology is identified in a minority of FN patients. In 2016 we implemented several evidence-based strategies to guide antibiotic use in high-risk FN patients including specifying vancomycin use indications, minimizing carbapenem escalation in stable patients with ongoing fevers, and defining antibiotic durations regardless of neutrophil count. The study objective was to characterize and evaluate our experience implementing these strategies on antibiotic use and clinical outcomes. METHODS: Interrupted time series analysis of all admissions to the Malignant Hematology service at the University of California, San Francisco between June 2014 and December 2018. The primary outcome was monthly days of therapy (DOT) per 1,000 patient-days of broad-spectrum IV antibiotics (aztreonam, cefepime, piperacillin–tazobactam, meropenem, and vancomycin). Secondary outcomes included DOT/1,000 patient-days for each IV antibiotic, incidence rates of bloodstream infections (BSI) and C. difficile infections (CDI), and in-hospital all-cause mortality. A segmented regression analysis was conducted to evaluate the impact of the FN management algorithm implementation on antibiotic use and clinical outcomes. Summary statistics and time series scatter plots were used to visualize the trends and outliers. RESULTS: 2319 unique patients with 6,788 encounters were included. The median (IQR) age was 59 (46–68) years and 60% were male. Regression results and time series plots are shown in Table 1 and Figures 1–3. CONCLUSION: Implementation of an evidence-based FN management algorithm led to decreased vancomycin and meropenem use without a statistically significant impact on overall antibiotic use, CDI rates, or mortality.While BSI rates fluctuated in the 2 months post-implementation, rates returned to baseline thereafter. A multidisciplinary effort facilitated successful implementation of this stewardship project. This collaboration remains essential to addressing future antimicrobial management strategies in this population. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810922
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68109222019-10-28 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis Trinh, Trang D Strnad, Luke Damon, Lloyd E Dzundza, John H Graff, Larissa R Griffith, Laura M Hilts-Horeczko, Alexandra Olin, Rebecca L Shenoy, Samantha DeVoe, Catherine Wang, Lusha Rodriguez-Monguio, Rosa Doernberg, Sarah B Open Forum Infect Dis Abstracts BACKGROUND: Febrile neutropenia (FN) is a common complication of cancer therapy and often necessitates prolonged antibiotic treatment. Antibiotic de-escalation can be challenging given tenuous clinical status. Furthermore, a microbiological or clinical etiology is identified in a minority of FN patients. In 2016 we implemented several evidence-based strategies to guide antibiotic use in high-risk FN patients including specifying vancomycin use indications, minimizing carbapenem escalation in stable patients with ongoing fevers, and defining antibiotic durations regardless of neutrophil count. The study objective was to characterize and evaluate our experience implementing these strategies on antibiotic use and clinical outcomes. METHODS: Interrupted time series analysis of all admissions to the Malignant Hematology service at the University of California, San Francisco between June 2014 and December 2018. The primary outcome was monthly days of therapy (DOT) per 1,000 patient-days of broad-spectrum IV antibiotics (aztreonam, cefepime, piperacillin–tazobactam, meropenem, and vancomycin). Secondary outcomes included DOT/1,000 patient-days for each IV antibiotic, incidence rates of bloodstream infections (BSI) and C. difficile infections (CDI), and in-hospital all-cause mortality. A segmented regression analysis was conducted to evaluate the impact of the FN management algorithm implementation on antibiotic use and clinical outcomes. Summary statistics and time series scatter plots were used to visualize the trends and outliers. RESULTS: 2319 unique patients with 6,788 encounters were included. The median (IQR) age was 59 (46–68) years and 60% were male. Regression results and time series plots are shown in Table 1 and Figures 1–3. CONCLUSION: Implementation of an evidence-based FN management algorithm led to decreased vancomycin and meropenem use without a statistically significant impact on overall antibiotic use, CDI rates, or mortality.While BSI rates fluctuated in the 2 months post-implementation, rates returned to baseline thereafter. A multidisciplinary effort facilitated successful implementation of this stewardship project. This collaboration remains essential to addressing future antimicrobial management strategies in this population. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810922/ http://dx.doi.org/10.1093/ofid/ofz360.953 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Trinh, Trang D
Strnad, Luke
Damon, Lloyd E
Dzundza, John H
Graff, Larissa R
Griffith, Laura M
Hilts-Horeczko, Alexandra
Olin, Rebecca L
Shenoy, Samantha
DeVoe, Catherine
Wang, Lusha
Rodriguez-Monguio, Rosa
Doernberg, Sarah B
1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis
title 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis
title_full 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis
title_fullStr 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis
title_full_unstemmed 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis
title_short 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis
title_sort 1089. implementation of a febrile neutropenia management algorithm on antibiotic use and outcomes: an interrupted time series analysis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810922/
http://dx.doi.org/10.1093/ofid/ofz360.953
work_keys_str_mv AT trinhtrangd 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT strnadluke 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT damonlloyde 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT dzundzajohnh 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT grafflarissar 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT griffithlauram 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT hiltshoreczkoalexandra 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT olinrebeccal 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT shenoysamantha 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT devoecatherine 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT wanglusha 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT rodriguezmonguiorosa 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis
AT doernbergsarahb 1089implementationofafebrileneutropeniamanagementalgorithmonantibioticuseandoutcomesaninterruptedtimeseriesanalysis